Seguir
Jesus Garcia-Donas
Jesus Garcia-Donas
Head of the Gynecological, Genitourinary and Skin Cancer Unit Hospital Madrid Norte Sanchinarro
Dirección de correo verificada de hmhospitales.com
Título
Citado por
Citado por
Año
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
15842017
Erdafitinib in locally advanced or metastatic urothelial carcinoma
Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ...
New England Journal of Medicine 381 (4), 338-348, 2019
10952019
Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ...
New England Journal of Medicine 381 (25), 2403-2415, 2019
7662019
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre …
J Garcia-Donas, E Esteban, LJ Leandro-García, DE Castellano, ...
The lancet oncology 12 (12), 1143-1150, 2011
2892011
Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer
EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, ...
JAMA oncology 3 (12), e173290-e173290, 2017
2792017
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
S Leskelä, C Jara, LJ Leandro-Garcia, A Martinez, J Garcia-Donas, ...
The pharmacogenomics journal 11 (2), 121-129, 2011
1612011
A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li–Fraumeni-like families
O Calvete, P Martinez, P Garcia-Pavia, C Benitez-Buelga, ...
Nature communications 6 (1), 8383, 2015
1582015
Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis
I Diaz-Padilla, N Romero, E Amir, X Matias-Guiu, E Vilar, F Muggia, ...
Critical reviews in oncology/hematology 88 (1), 154-167, 2013
1382013
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
E Grande, J Capdevila, D Castellano, A Teulé, I Durán, J Fuster, I Sevilla, ...
Annals of oncology 26 (9), 1987-1993, 2015
1352015
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ...
The Lancet Oncology 23 (3), 362-373, 2022
1222022
Prognostic gene expression signature for high-grade serous ovarian cancer
J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, ...
Annals of oncology 31 (9), 1240-1250, 2020
1042020
Strategies to design clinical studies to identify predictive biomarkers in cancer research
JL Perez-Gracia, MF Sanmamed, A Bosch, A Patiño-Garcia, KA Schalper, ...
Cancer Treatment Reviews 53, 79-97, 2017
1032017
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma
C Prior, JL Perez-Gracia, J Garcia-Donas, C Rodriguez-Antona, ...
PloS one 9 (1), e86263, 2014
1012014
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled …
JA Ledermann, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet Oncology 21 (5), 710-722, 2020
1002020
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma
MHM Diekstra, JJ Swen, E Boven, D Castellano, H Gelderblom, ...
European urology 68 (4), 621-629, 2015
952015
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
AO Siefker-Radtke, A Necchi, SH Park, J García-Donas, RA Huddart, ...
The lancet oncology 23 (2), 248-258, 2022
902022
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J Garcia-Donas, LJ Leandro-Garcia, AG Del Alba, M Morente, I Alemany, ...
Annals of oncology 24 (9), 2409-2414, 2013
902013
Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
M Apellániz-Ruiz, MY Lee, L Sánchez-Barroso, G Gutiérrez-Gutiérrez, ...
Clinical Cancer Research 21 (2), 322-328, 2015
792015
Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB
L Minig, MG Patrono, N Romero, JFR Moreno, J Garcia-Donas
World journal of clinical oncology 5 (2), 86, 2014
762014
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
PF Rambau, RA Vierkant, MP Intermaggio, LE Kelemen, MT Goodman, ...
The Journal of Pathology: Clinical Research 4 (4), 250-261, 2018
752018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20